Bayer

# Investor News 2017

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

The news contents can be obtained from our website www.investor.bayer.com

| Date | News |
|---|---|
| December 20, 2017 | Not intended for U.S. and UK Media<br>**Bayer announces initiation of rolling submission of new drug application in the U.S. for Larotrectinib for the treatment of TRK fusion cancers**<br>Completion of NDA submission expected in early 2018 |
| December 13, 2017 | Not intended for U.S. and UK Media<br>**Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer**<br>Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) |
| December 11, 2017 | Not intended for U.S. and UK Media<br>**Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease**<br>- The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack<br>- The application for marketing approval is based on the COMPASS study |
| December 04, 2017 | Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research:<br>**Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers**<br>- 93 percent overall response rate in 17 pediatric patients with TRK fusion cancers<br>- 94 percent of all patients remain on larotrectinib or received surgery with curative intent, four patients have been followed greater than one year and 12 have been followed greater than six months<br>- Larotrectinib demonstrates central nervous system activity in first-ever TRK fusion glioblastoma response with a TRK inhibitor |
| December 01, 2017 | **CFIUS completes review of proposed merger of Bayer and Monsanto** |
| November 30, 2017 | Not intended for U.S. and UK Media<br>**Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early**<br>Decision follows a recommendation from an Independent Data Monitoring Committee |
| November 24, 2017 | Not intended for U.S. and UK Media<br>**Phase III study program with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority** |
| November 15, 2017 | **Heiko Schipper to join Bayer Board of Management and head Consumer Health Division**<br>Erica Mann to leave Bayer effective March 31, 2018 |

| Date | News |
|---|---|
| November 14, 2017 | Not intended for U.S. and UK Media<br>**Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer**<br>- Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors<br>- Co-Promotion of the products in the U.S.<br>- Bayer solely responsible for the commercialization of both products outside the U.S.<br>- U.S. filing of larotrectinib planned for late 2017 or early 2018 |
| November 06, 2017 | Not intended for U.S. and UK Media<br>**Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency**<br>- The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack<br>- The application for marketing approval is based on the COMPASS study<br>- If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient population |
| October 30, 2017 | Not intended for U.S. and UK Media<br>**Bayer receives FDA approval for Xarelto® 10 mg once daily for the extended treatment of venous thromboembolism**<br>- Rivaroxaban (Xarelto®) 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily following at least six months of standard anticoagulation therapy<br>- FDA approval based on data from the EINSTEIN CHOICE study |
| October 26, 2017 | Third quarter of 2017:<br>**Bayer: Sales and earnings increased**<br>- Covestro deconsolidated<br>- Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million<br>- EBITDA before special items up by 4.1 percent to EUR 2,204 million<br>- Sales and earnings growth at Pharmaceuticals<br>- Consumer Health business weak, as expected<br>- Sales gains at Crop Science and Animal Health<br>- Net income of EUR 3,881 million including Covestro book profit<br>- Core earnings per share at EUR 1.47 (minus 3.9 percent)<br>- Group outlook for 2017 confirmed based on change in structure |
| October 17, 2017 | Not intended for U.S. and UK Media<br>**Bayer submits its extended half-life Hemophilia A compound for marketing authorization in Japan**<br>Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals |
| October 13, 2017 | Milestone on Bayer's path to completing the planned acquisition of Monsanto:<br>**Bayer signs agreement to sell selected Crop Science businesses to BASF for EUR 5.9 billion**<br>- Package includes global glufosinate-ammonium business and selected seeds activities<br>- Assets generated total sales of EUR 1.3 billion in 2016<br>- Sale is subject to successful closing of Bayer's acquisition of Monsanto<br>- BASF has committed to maintain employment for all transferring permanent employees for at least three years post closing |

| Date | News |
|---|---|
| October 05, 2017 | Not intended for U.S. and UK Media<br>**Bayer's NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms**<br>- Phase III NAVIGATE ESUS study evaluated rivaroxaban vs aspirin in patients with embolic stroke of undetermined source (ESUS)<br>- The study at interim indicates no efficacy improvement over low dose aspirin and very little chance of showing overall benefit if the study were completed<br>- The positive benefit risk profile of rivaroxaban remains unchanged in all licensed indications |
| September 29, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN<br>**Bayer cedes control of Covestro**<br>A further 6.9 percent of Covestro shares sold for EUR 1 billion / Control termination agreement reached, effective September 30, 2017 |
| September 19, 2017 | Future of Farming Dialog 2017:<br>**Crop Science Division of Bayer well positioned to fulfill future customer, market and societal needs**<br>- Global seed and crop protection market will continue to grow<br>- Business in Brazil expected to return to normal in 2018<br>- Progress being made in planned Monsanto acquisition<br>- Anticipated closing in early 2018<br>- Planned R&D investment of approximately EUR 1 billion in 2017<br>- R&D efforts to bring 15 new products to farmers between 2017 and 2020<br>- Strong focus on innovation and sustainability<br>- Commitment to transparency |
| September 15, 2017 | Not intended for U.S. and UK Media<br>**Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism**<br>- Rivaroxaban 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily after at least six months of standard anticoagulation therapy<br>- Positive CHMP Opinion is based on data from the Phase III EINSTEIN CHOICE study<br>- Final European Commission decision expected by November 2017 |
| September 14, 2017 | Not intended for U.S. and UK Media<br>**Bayer receives FDA approval for Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies**<br>- Accelerated approval based on overall response rate (ORR) of 104 adult patients with relapsed follicular lymphoma (FL) from the Phase II CHRONOS-1 study<br>- Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial<br>- Copanlisib achieved a 59% ORR in patients with relapsed FL [n=104 (95%CI 49,68)]<br>- First approval of an intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor |
| September 13, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN<br>**Bayer places 9.4 percent stake in Covestro** |
| September 12, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN<br>**Bayer further reduces holding in Covestro**<br>Accelerated bookbuilding process started |
| September 12, 2017 | **Wolfgang Nickl to be new Chief Financial Officer at Bayer AG** |

| Date | News |
|---|---|
| September 07, 2017 | Not intended for U.S. and UK Media<br>**Bayer submits marketing authorization application for BAY94-9027 for the treatment of Hemophilia A in the EU**<br>Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals |
| August 31, 2017 | Not intended for U.S. and UK Media<br>**Bayer submits Biologics License Application in the U.S. for BAY94-9027 - a long-acting factor VIII for the treatment of Hemophilia A**<br>Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals |
| August 30, 2017 | Not intended for U.S. and UK Media - 17th European Society of Retina Specialists (EURETINA) Congress<br>**Bayer to showcase latest Ophthalmology research at EURETINA 2017** |
| August 27, 2017 | Not intended for U.S. and UK Media - Data from COMPASS study, including 27,395 patients, presented at ESC Congress 2017:<br>**Bayer's Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24%**<br>- Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone<br>- Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding<br>- This combination regimen demonstrated a substantial improvement in net clinical benefit of 20% |
| August 22, 2017 | Phase II investigation of the proposed combination of Bayer and Monsanto:<br>**Bayer will continue to work constructively with the European Commission** |
| August 21, 2017 | Not intended for U.S. and UK Media<br>**Two abstracts on Phase III COMPASS study with Bayer's Rivaroxaban accepted for presentation in Hot Line sessions at ESC Congress 2017**<br>- Results from COMPASS, the largest clinical study of rivaroxaban to date, will provide new insights into the management of patients with chronic coronary and peripheral artery disease<br>- COMPASS study was stopped early because of overwhelming efficacy<br>- A total of 17 rivaroxaban abstracts accepted for presentation covering both clinical and real-world studies in venous and arterial thromboembolism |
| August 07, 2017 | Not intended for U.S. and UK Media<br>**Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer**<br>- Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)<br>- Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States for patients with HCC |

| Date | News |
|---|---|
| July 27, 2017 | Second quarter of 2017:<br>**Bayer: Group performance matches prior year despite declines at Crop Science**<br>- Group sales increase by 3.0 percent (Fx & portfolio adj.: plus 1.9 percent) to EUR 12,193 million<br>- EBITDA before special items level with the prior year, at EUR 3,056 million (plus 0.1 percent)<br>- Pharmaceuticals posts strong increase in earnings and margins<br>- Brazil business weighs on Crop Science<br>- Consumer Health encounters difficult market environment in the United States<br>- Significant increase in sales and earnings at Covestro<br>- Net income decreases by 11.3 percent to EUR 1,224 million<br>- Core earnings per share EUR 1.81 (minus 12.6 percent)<br>- Monsanto acquisition on track<br>- Group outlook for 2017 adjusted |
| July 21, 2017 | Not intended for U.S. and UK Media<br>**Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma** |
| July 21, 2017 | Not intended for U.S. and UK Media<br>**Bayer's Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement**<br>- Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1)<br>- PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population<br>- Final decision of European Commission expected by the end of this year |
| July 03, 2017 | Not intended for U.S. and UK Media<br>**Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids** |
| June 30, 2017 | **Bayer expects negative earnings impact from its Brazilian Crop Science business** |
| June 26, 2017 | Not intended for U.S. and UK Media<br>**Bayer Receives Approval for Stivarga® in Japan for Second-Line Treatment of Hepatocellular Carcinoma**<br>- Stivarga® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade<br>- Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcinoma (HCC) with Stivarga directly after Nexavar® (sorafenib) |
| June 23, 2017 | Not intended for U.S. and UK Media<br>**Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer**<br>- Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)<br>- Approval could provide first treatment advance in nearly a decade<br>- Final decision from the European Commission anticipated within the next two months |

| Date | News |
|---|---|
| June 07, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN<br>**Bayer places 8.5 percent of Covestro's shares and EUR 1 billion bonds exchangeable into Covestro shares** |
| June 06, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN<br>**Bayer further reduces stake in Covestro**<br>- Accelerated bookbuilding and bonds exchangeable into Covestro shares offered<br>- Bayer to deposit 8 million Covestro shares in Bayer Pension Trust e. V. |
| May 17, 2017 | Not intended for U.S. and UK Media<br>**Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib**<br>- Regulatory submission based on data from the Phase II CHRONOS-1 study, in which copanlisib showed objective response rate of 59% and a manageable safety profile in patients with follicular lymphoma (FL)<br>- Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms<br>- Copanlisib granted Fast Track and Orphan Drug Designation in the U.S. for FL |
| April 28, 2017 | Not intended for U.S. and UK Media<br>**Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism**<br>- If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose<br>- Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped<br>- Application to FDA supported by data from the EINSTEIN CHOICE study |
| April 28, 2017 | CEO Werner Baumann at the Annual Stockholders' Meeting of Bayer AG:<br>**"We want to further strengthen Bayer"**<br>- Acquisition of Monsanto to create substantial additional value<br>- Record sales and earnings in 2016<br>- Dividend increase to EUR 2.70 per share proposed<br>- Employees to share in the company's success through total bonuses of over EUR 1.4 billion<br>- Successful start to fiscal 2017 |
| April 28, 2017 | Not Intended for U.S. or UK Media<br>**Bayer Receives FDA Approval for Stivarga® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer**<br>- Stivarga is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)<br>- First new treatment for HCC in a decade<br>- Pivotal Phase III RESORCE trial defines a new treatment plan in HCC which involves use of Stivarga directly after progression on Nexavar |
| April 27, 2017 | **Supervisory Board of Bayer AG extends service contract of CFO Johannes Dietsch to the end of May 2018** |

| Date | News |
|---|---|
| April 27, 2017 | Interim report for the first quarter of 2017:<br>**Strong start to the year for Bayer**<br>- Group sales increase by 11.7 percent (Fx & portfolio adj.: 9.4 percent) to EUR 13,244 million<br>- EBITDA before special items raised by 14.9 percent to EUR 3,893 million<br>- Growth momentum across all segments<br>- Very good business development at Pharmaceuticals<br>- Significant increase in sales and earnings at Covestro<br>- Net income 37.9 percent higher at EUR 2,083 million<br>- Core earnings per share advance by 11.5 percent to EUR 2.62<br>- Group outlook for 2017 raised, driven by Covestro performance |
| March 31, 2017 | Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 108th Annual Meeting:<br>**Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkin's Lymphoma**<br>- Copanlisib achieves objective tumor response rate of 59% in indolent Non-Hodgkin's Lymphoma (iNHL) patients with a manageable safety profile in CHRONOS-1 study<br>- Data to be featured in an oral presentation in a Clinical Trials session on April 4 at AACR<br>- Bayer in discussion with the U.S. Food and Drug Administration regarding a filing for an accelerated approval of copanlisib in follicular lymphoma (FL), a subset of iNHL<br>- Copanlisib granted Fast Track Designation in the U.S. for FL and Orphan Drug Designation in the U.S. for FL and marginal zone lymphoma |
| March 22, 2017 | Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 108th Annual Meeting:<br>**Bayer to Showcase Data on Growing Oncology Pipeline at AACR 2017**<br>- Results from pivotal Phase II trial CHRONOS-1 of investigational PI3K inhibitor copanlisib selected for oral presentation at Congress' Clinical Trial Session<br>- Early research findings from across the company's oncology development portfolio will also be presented |
| March 18, 2017 | Not intended for U.S. and UK Media - New Late-Breaking Study Data Presented at ACC.17:<br>**Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study**<br>- Study with more than 3,000 patients investigated rivaroxaban 10 mg and 20 mg once daily versus aspirin 100 mg once daily<br>- Both rivaroxaban treatment arms were superior in preventing recurrent venous thromboembolism while showing comparable and very low rates of major bleeding versus aspirin<br>- Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped<br>- Data were presented in a late-breaking clinical trial session at ACC.17 and published simultaneously in The New England Journal of Medicine |
| March 06, 2017 | Not intended for U.S. and UK Media - American College of Cardiology 66th Annual Scientific Session (ACC.17):<br>**EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17** |
| March 01, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA<br>**Bayer places 10.9 percent of Covestro's shares with institutional investors**<br>Holding in Covestro reduced to 53.3 percent |
| February 28, 2017 | NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA - Accelerated bookbuilding process started:<br>**Bayer to reduce holding in Covestro**<br>Majority stake maintained for the time being |

| Date | News |
|---|---|
| February 22, 2017 | Fiscal 2016:<br>**Another record year for Bayer - good progress with the acquisition of Monsanto**<br>- Group sales increase by 1.5 percent (Fx & portfolio adj. 3.5 percent) to EUR 46,769 million<br>- Substantial sales and earnings increases at Pharmaceuticals<br>- Consumer Health grows with competition<br>- Crop Science successful in a difficult market environment<br>- EBITDA before special items improves by 10.2 percent to EUR 11,302 million<br>- Net income raised by 10.2 percent to EUR 4,531 million<br>- Core earnings per share increase by 7.3 percent to EUR 7.32<br>- Operating cash flow climbs by 20.8 percent to EUR 8,259 million<br>- Forecast for 2017: further growth in sales and earnings |
| February 21, 2017 | **Bayer proposes increased dividend for 2016 of EUR 2.70 per share**<br>Total dividend payout rises 8 percent to EUR 2,233 million |
| February 08, 2017 | Not intended for U.S. and UK Media<br>**Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early**<br>- Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke<br>- Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient population |
| January 20, 2017 | Not intended for U.S. and UK Media<br>**Regorafenib from Bayer Granted Priority Review in Japan for the Second-Line Treatment of Liver Cancer** |
| January 04, 2017 | Not intended for U.S. and UK Media<br>**Regorafenib from Bayer Granted Priority Review in the U.S. for Second-Line Treatment of Liver Cancer** |